The Federal Drug Administration (FDA) has approved a new once-daily weight-loss pill from Eli Lilly, adding to the bevy of GLP-1 medications available in the consumer marketplace. The drug ...

The Food and Drug Administration on Wednesday approved a new weight loss pill from drugmaker Eli Lilly. Subscribe to read this story ad-free Get unlimited access to ad-free articles and exclusive ...

April 1 (UPI) --The Food and Drug Administration on Wednesday approved Eli Lilly's pill version of a GLP-1 medication for weight loss, making it the second company to offer a non-injectable version of ...

These days, just about everyone is recommending a different way to lose weight. Whether it’s the latest ultra-low-fat diet, high-intensity exercise regimes like CrossFit or medications injected weekly ...

View post: Dodgers Make Trade After 18th Game of MLB Season Dybantsa was not the issue for them at all. Texas was able to overcome his strong performance anyways. The Longhorns advanced to the next ...

The No. 11 Texas Longhorns outlasted AJ Dybantsa and the No. 6 seed BYU Cougars in the opening round matchup in the West Region of the 2026 NCAA Tournament, winning by a score of 79-71. The Longhorns ...

Eli Lilly’s LLY-1.65%decrease; red down pointing triangle experimental weight-loss drug retatrutide met the primary and key secondary endpoints in a trial, showing significant improvements in weight ...

For years, people with prediabetes have been told the same thing: lose weight or risk developing diabetes. But new research flips that idea on its head, showing that blood sugar can return to normal ...

A new class of weight-loss drug just took a major step toward approval for use. In a phase 3 clinical trial, the medication retatrutide helped control blood sugar levels in participants with type 2 ...

ALBUQUERQUE, N.M. — When it comes to weight loss, it’s good to know what healthy weight loss looks like and how little gains actually are a lot. Trainer Flip Garcia, with MiLEO Fitness brought in some ...

Kendra Pierre-Louis: For Scientific American’s Science Quickly, I’m Kendra Pierre-Louis, in for Rachel Feltman. In early March the U.S. Food and Drug Administration sent a warning letter to Novo ...